Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 21, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 790,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,624 pence per share; lowest price paid was 1,598.50 pence per share.
- Treasury Holdings (Settled): 512,049,512 shares (9.43% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,189,512 shares (10.46% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,918,100,404 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 790,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.46% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (512,049,512 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding Treasury shares (4,918,100,404) for voting rights calculations.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial statements.